These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

127 related items for PubMed ID: 2207328

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Site-directed mutagenesis of alanine-382 of human antithrombin III.
    Austin RC, Rachubinski RA, Blajchman MA.
    FEBS Lett; 1991 Mar 25; 280(2):254-8. PubMed ID: 2013320
    [Abstract] [Full Text] [Related]

  • 6. Antithrombin Glasgow II: alanine 382 to threonine mutation in the serpin P12 position, resulting in a substrate reaction with thrombin.
    Ireland H, Lane DA, Thompson E, Walker ID, Blench I, Morris HR, Freyssinet JM, Grunebaum L, Olds R, Thein SL.
    Br J Haematol; 1991 Sep 25; 79(1):70-4. PubMed ID: 1911389
    [Abstract] [Full Text] [Related]

  • 7. Purification and characterization of hereditary abnormal antithrombin III with impaired thrombin binding.
    Jørgensen M, Petersen LC, Thorsen S.
    J Lab Clin Med; 1984 Aug 25; 104(2):245-56. PubMed ID: 6747440
    [Abstract] [Full Text] [Related]

  • 8. Mechanisms responsible for catalysis of the inhibition of factor Xa or thrombin by antithrombin using a covalent antithrombin-heparin complex.
    Paredes N, Wang A, Berry LR, Smith LJ, Stafford AR, Weitz JI, Chan AK.
    J Biol Chem; 2003 Jun 27; 278(26):23398-409. PubMed ID: 12695507
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Expression of functionally active human antithrombin III.
    Stephens AW, Siddiqui A, Hirs CH.
    Proc Natl Acad Sci U S A; 1987 Jun 27; 84(11):3886-90. PubMed ID: 3473488
    [Abstract] [Full Text] [Related]

  • 11. Heparin and ionic strength-dependent conversion of antithrombin III from an inhibitor to a substrate of alpha-thrombin.
    Olson ST.
    J Biol Chem; 1985 Aug 25; 260(18):10153-60. PubMed ID: 4019506
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Molecular weight analysis of antithrombin III-heparin and antithrombin III-thrombin-heparin complexes.
    Pletcher CH, Cunningham MT, Nelsestuen GL.
    J Biol Chem; 1986 Mar 25; 261(9):4143-7. PubMed ID: 3949807
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Autoantibodies to vascular heparan sulfate proteoglycan in systemic lupus erythematosus react with endothelial cells and inhibit the formation of thrombin-antithrombin III complexes.
    Shibata S, Sasaki T, Harpel P, Fillit H.
    Clin Immunol Immunopathol; 1994 Feb 25; 70(2):114-23. PubMed ID: 8299226
    [Abstract] [Full Text] [Related]

  • 19. Isolation and characterization of an antithrombin III variant with reduced carbohydrate content and enhanced heparin binding.
    Peterson CB, Blackburn MN.
    J Biol Chem; 1985 Jan 10; 260(1):610-5. PubMed ID: 3965464
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.